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Abstract. Adsorptive-mediated transcytosis (AMT) provides a means for brain delivery of medicines
across the blood-brain barrier (BBB). The BBB is readily equipped for the AMT process: it provides
both the potential for binding and uptake of cationic molecules to the luminal surface of endothelial cells,
and then for exocytosis at the abluminal surface. The transcytotic pathways present at the BBB and its
morphological and enzymatic properties provide the means for movement of the molecules through the
endothelial cytoplasm. AMT-based drug delivery to the brain was performed using cationic proteins and
cell-penetrating peptides (CPPs). Protein cationization using either synthetic or natural polyamines is
discussed and some examples of diamine/polyamine modiﬁed proteins that cross BBB are described. Two
main families of CPPs belonging to the Tat-derived peptides and Syn-B vectors have been extensively
used in CPP vector-mediated strategies allowing delivery of a large variety of small molecules as well as
proteins across cell membranes in vitro and the BBB in vivo. CPP strategy suffers from several limitations
such as toxicity and immunogenicity—like the cationization strategy—as well as the instability of peptide
vectors in biological media. The review concludes by stressing the need to improve the understanding of
AMT mechanisms at BBB and the effectiveness of cationized proteins and CPP-vectorized proteins as
neurotherapeutics.
KEY WORDS: adsorptive-mediated transcytosis; blood-brain barrier; cationic proteins; cell-penetrating
peptides.
INTRODUCTION
In the past decade, many potential protein-based large
molecule drugs and non-viral gene medicines have success-
fully been developed for therapeutic and/or diagnostic
applications. In contrast to small drugs, these large molecules
have often seen a limited pharmaceutical development or use
as clinically-viable drugs. This is due to their low permeability
to the plasma membrane resulting in poor cellular access.
This limited access largely prohibits them from reaching
appropriate sites (i.e. interior of cells and tissues) and from
crossing epithelial and endothelial barriers. An extreme
example of this latter difﬁculty is the delivery of large and/
or hydrophilic molecules to the brain.
In spite of its dense capillary network, the brain
(400 miles of capillaries with a surface area of 12 m
2 in the
human brain) (1) is probably one of the least accessible
organs to circulating compounds. The dichotomy is that
permeability of the brain capillary endothelium forming the
blood-brain-barrier (BBB) is about two orders of magnitude
lower than that of endothelia in peripheral organs (2). The
BBB is a nonfenestrated endothelium with narrow tight
junctions between the endothelial cells (EC) which prevent
the passage from blood to brain interstitium of water-soluble
compounds via aqueous paracellular pathways (3). Circulating
molecules may, therefore, pass from blood to brain only by
one of two transcellular mechanisms: passive diffusion or
catalyzed transport. As a general rule, the transcellular
diffusion of a substance across the BBB depends on its lipid
solubility, molecular mass and charge. Peptides and proteins
are generally excluded from passive transport because of their
hydrophilicity and/or molecular mass.
Biologics, such as those mentioned above, can be
delivered to the brain via vesicular transport across the
BBB known as transcytosis. This type of transport describes
the vectorial movement of molecules within endocytic vesicles
and across the cerebral EC, from the luminal cell side to the
abluminal side where exocytosis occurs. The brain capillary
ECs contain two kinds of vesicles that are open to the luminal
blood capillary space: the caveolae, also called plasmalemmal
vesicles, and the clathrin-coated pits/vesicles (Fig. 1). Soluble
plasma molecules can be randomly taken up by caveolae with
a bulk of blood plasma, and then be transported across
cerebral ECs. This transport process, known as bulk-phase or
ﬂuid-phase transcytosis (FMT), is independent of any inter-
action between the transported molecules and the caveolar
vesicle membrane (4). While FMT represents the main
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herve@univ-paris5.fr)transport process for the transendothelial delivery of proteins
from blood to underlying tissues in the periphery (4), this
process occurs to a very limited degree in a healthy BBB,
because of the rare occurrence of caveolae in the brain
capillaries (2). Nevertheless, tiny amounts of some proteins
can be transported in this way across the BBB (Table I). In
contrast, the brain capillary ECs are characterized by a high
density of clathrin-coated pits/vesicles (5). Because the
clathrin-coated pits that open at the luminal brain endothelial
surface are negatively charged (Fig. 1), they will repel anionic
molecules. Thus, only a very small portion of the plasma
proteins can be transcytosed randomly within the ﬂuid phase
of transport clathrin-coated vesicles.
Molecules can be transcytosed by adsorption to the
clathrin-coated or caveolar vesicle membrane. In contrast to
FMT, adsorptive transcytosis requires the interaction of a
ligand with moieties expressed at the luminal surface of
cerebral EC. It can be divided into specific (receptor-mediated
transcytosis; RMT) and nonspecific (adsorptive-mediated
transcytosis; AMT) processes. The former is triggered by a
speciﬁc interaction with receptors expressed on cerebral EC.
A limited set of proteins and peptides are transported across
the BBB via RMT (Table I), the three best-studied ligands
being insulin, iron-transferrin and LDL-cholesterol (2). Both
insulin and transferrin receptors are enriched in cerebral ECs,
but relatively tiny amounts of insulin and transferrin are
delivered into the brain mass via RMT. These small quantities
are often sufﬁcient to maintain BBB and brain homeostasis
through hormonal effects (i.e. insulin) or by supplying
essential molecules such as iron and cholesterol (2). Molecules
that penetrate the brain via AMT include, but are not limited
to, various cationic proteins (Table I).
Many brain drug delivery strategies have focused on
RMT and AMT, although the RMT pathway has been used
more actively because speciﬁcity is preferable, especially for
toxic agent delivery (e.g. anti-cancer drugs). In this view, the
brain endothelial transferrin and insulin receptor transport
systems have been given particular attention (1,6). More
speciﬁcally, the anti-transferrin receptor antibody, OX26,
which is transcytosed into the brain mass, has been used to
shuttle biologics chemically attached to the antibody or
encapsulated into antibody-functionalized carriers (immuno-
liposomes) across the BBB (7). Because the amounts of
OX26 antibody delivered to the brain are extremely low
(<1% of the dose injected), and as there is no deﬁnitive
evidence for quantitative transcytosis of the receptor along
with the cargo, this approach is being combined with other
molecules that transiently open tight junctions to deliver
macromolecule drugs (8). Therefore and because of the
increasing need to solve the BBB drug delivery problem,
increasing attention has been paid to the potential of AMT in
protein-based-drug discovery.
ADSORPTIVE-MEDIATED TRANSCYTOSIS
AND ITS PROPERTIES
Origin of the Concept
The concept of AMT through the BBB originated with
the observation that polycationic proteins such as protamine
could not only bind to the endothelial cell surface but could
also penetrate the BBB (9). Moreover, mixing protamine,
poly-L-lysine or other cationic molecules with proteins (e.g.
albumin and horseradish peroxidase) greatly increased the
permeability of these proteins across cerebral microvessels
(9,10). This could probably be due to their binding afﬁnity for
polycations. In a similar manner, cationized proteins can be
transported through the BBB (1). These ﬁndings were
explained by adsorptive-mediated endocytosis triggered by
electrostatic interactions between the positively charged
moieties of the proteins and negatively charged membrane
surface regions on the brain ECs (11). As a consequence, the
cationic net charge of a peptide/protein has gradually become
recognized as an important determinant in the brain capillary
uptake of these molecules.
AMT and the BBB
The BBB is readily equipped for the AMT process: it
provides both the potential for binding of cationic molecules
to the luminal surface of endothelial cells, and then for
exocytosis at the abluminal surface; the transcytotic pathways
present at the BBB and its morphological and enzymatic
properties, as well as the high content of mitochondria in
cerebral ECs provide the means for movement of the
molecules through the endothelial cytoplasm.
Glycocalyx and Negative Charges at the BBB Surface
At systemic physiological pH, the luminal surface of
cerebral ECs presents an overall negative charge. Early
ultrastructural studies (12) established that sialo-glycoconju-
gates and heparan sulfate proteoglycans, which constitute the
glycocalyx, provided the negative charge barrier. Moreover,
not only could anionic sites be described on the luminal
surface of cerebral ECs, but also on the abluminal surface.
Fig. 1. The luminal surface of endothelial cells of an adult mouse
brain capillary labeled with cationized bovine serum albumin-gold
conjugate (gold particle size: 5 nm). After 3 min of brain perfusion in
situ, the gold particles, distributed in small clusters on the luminal
plasma membrane (pm), also mark the negative charges associated
with the membrane of coated pits (cp) open to the luminal front of
endothelial cells, and coated vesicles (cv). In contrast, the luminal
caveolae (c) are not signiﬁcantly labeled by the cationic marker.
Furthermore, the gold particles do not penetrate beyond the tight
junctions (j). Bar: 100 nm. Other abbreviations: bl, basal lamina; End,
endosomal compartment (N. Ghinea, unpublished results)
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457 CNS Delivery Via Adsorptive TranscytosisCombinations of enzymatic treatments and cationic tracers,
however, demonstrated distinct differences between these
two surfaces (12). A more intense labeling of the luminal
surface with cationic colloidal gold was reached, indicating a
polar distribution of anionic components of the plasma
membrane (Fig. 2). The anionic sites of the luminal front
mainly represent carboxyl groups of sialic acid-containing
glycoproteins which can be digested with neuraminidase, and
to a lesser degree, sulfate groups of heparan sulfate proteo-
glycans. The abluminal anionic sites are neuraminidase-
resistant, and are in fact digested by an heparinase that
cleaves heparan sulfates. These mainly consist of mixed
proteoglycans. Heparan sulfates are the main glycosamino-
glycans (GAGs) of the endothelial cell glycocalyx. The
dominating heparan sulfate proteoglycans (HSPGs) at the
endothelial cell surface are the syndecans and glypicans (for
further details, see Fig. 3). It has to be stressed that HSPGs
are suspected of playing a critical role in cellular internaliza-
tion of basic peptides, growth-promoting polyamines and
polycation-nucleic acid complexes, with possible applications
associated with protein delivery and gene transfer into cells
(13). The basement membrane contiguous to the basolateral
side of the cerebral ECs is also a negatively charged barrier
due to its chondroitin and heparan sulfate-rich GAG
components. Perlecan, the least common among HSPGs, is
located within the basement membrane. All three of these
successive electrostatic barriers create an environment selec-
tivetopositivelychargedsubstances(Fig.2). The carbohydrate-
rich layer which extends into the capillary lumen provides
anionic sites (i.e. carboxyl groups of sialic acid residues) for the
binding of cationic substances to the luminal side of cerebral
ECs. The anionic properties of both the abluminal cell side and
the basement membrane (i.e. the sulfate groups of GAG
components) may facilitate the externalization of cationic
substances from the lumen of the transport vesicles, and their
transfer to the brain interstitium.
Morphological, Enzymatic and Energy Properties
The wall thickness of brain capillaries is roughly 40%
lower relative to peripheral capillaries (14). It has been
suggested that this difference may be a modulation of the
restrictive permeability of the BBB, allowing substances a
shortened transport time to cross through the membrane and
cytoplasm of the EC and enter the brain parenchyma.
Transcytosis of molecules at the BBB is an energy-
requiring/ATP-dependent transport process, both for the
endocytosis of the transported molecule at the luminal side
of the EC and for its transport across the EC as well as for its
exocytosis at the basolateral side. The density of mitochon-
dria in cerebral EC is roughly ﬁve times greater than in
peripheral endothelia (15), increasing the energy potential of
the BBB as well. This enhanced cerebral capillary work
capacity may be related to energy-dependent transcapillary
vesicular transport. Exocytosis of the molecules from the
vesicular compartment requires the fusion of the vesicle
membrane with the plasma membrane, a process presumably
regulated by protein phosphorylation and dephosphorylation
(16). With regard to this, the brain capillary endothelium has
a high activity of both protein kinases and phosphatases
involved in protein phosphorylation (17).
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458 Hervé, Ghinea and ScherrmannTranscytotic Pathways Across the BBB
This stage of transcytosis at the BBB starts with uptake
either through clathrin-coated pits or caveolae. The best-
studied of the two is that involving clathrin, which forms
coated membrane invaginated structures or pits on the
plasma membrane. As mentioned above, the brain capillary
endothelium is particularly enriched in clathrin-coated pits/
vesicles, compared to peripheral endothelia (5). Caveolae are
ﬂask-shaped, non-coated membrane invaginations, which are
characterized by their association with caveolin and their
enrichment in cholesterol and glycosphingolipids. Molecules
found within caveolae, such as glycosyl phosphatidyl inositol
(GPI)-anchored proteins, are not present in the coated pits.
Conversely, typical markers for clathrin-mediated endocyto-
sis, such as the transferrin-receptor, are not present in
caveolae. Clathrin-coated pits and caveolae are found at both
the luminal and abluminal plasma membranes of the cerebral
ECs. However, the clathrin-coated pits are much more
abundant at the luminal than at the abluminal side (5),
indicating that transcytosis mediated by the clathrin pathway
will mainly function unidirectionally, i.e. from blood to brain
(Fig. 4). This also applies to transcytosis mediated by
caveolae, but again, the brain ECs have a low frequency of
plasmalemmal vesicles (<100/μm
3)( 2). In both cases, the
clathrin-coated pits and caveolae provide the potential to
mediate endocytosis and to function in the transcellular
movement of selected molecules (18,19).
Clathrin-coated pits recruit cell-surface receptors and
then, through a series of highly regulated steps, pinch off to
form clathrin-coated vesicles. While some receptors may be
predominantly localized in the coated pits, even in the
absence of ligand binding, others such as the transferrin
receptor, accumulate selectively in coated pits only upon
ligand binding (20). As demonstrated in peripheral blood
vessels, caveolae may contain an abundance of membrane
receptors and transporters, as well as signaling molecules,
which suggests their possible involvement in various impor-
tant cellular processes, in addition to their role in the
endocytosis/transcytosis of speciﬁc molecules (19).
The coated pits and the caveolae mediate the trans-
cytosis of different sets of molecules across endothelial
barriers. As illustrated for the BBB in Fig. 4, the caveolae
may bud to form free, apparently intact (no caveolin
uncoating) vesicles for direct transendothelial transport to
underlying tissue cells (19). At the same time, once the
clathrin-coated vesicles have formed, they lose their clathrin
coat and the uncoated vesicles may fuse with a transcytotic
endosome (21) (Fig. 4). From there, the internalized recep-
tors and ligands may cross the cell and be delivered to the
opposite membrane (transcytosis).
Alternatively, the molecules internalized in clathrin-
coated vesicles or caveolae can trafﬁc through the brain
ECs to allow for accumulation in lysosomes for degradation.
As demonstrated in peripheral microsvascular ECs, the
degradative endocytic pathways mediated by the caveolae
and by the clathrin-coated vesicles differ in some early
aspects (19). However, with time, ligands internalized by
caveolae ﬁnally converge with ligands of the clathrin-coated
vesicle pathway within later-stage endosomes and lysosomes.
The vesicular route used for the transcytosis of cationic
substances through the BBB is not well known. What is
known is that AMT may not involve speciﬁcp l a s m a
membrane receptors and that endocytosis is initiated through
Fig. 2. Endothelial cell surface and basement membrane components bearing anionic charges at the
blood-brain barrier, which allow the adsorptive-mediated transcytosis of cationic substances. Abbrevia-
tions: HSPGs, heparan sulfate proteoglycans; CSPGs, chondroitin sulfate proteoglycans; J, tight junction
459 CNS Delivery Via Adsorptive Transcytosischarge-charge interaction between polycationic substances
and negative charges on the endothelial surface. The clathrin-
coated pits along the luminal surface of ECs are negatively
charged (Fig. 1), and thus capable of binding positively
charged substances. Moreover, glycoprotein receptors that
concentrate in coated pits, such as the transferrin receptor
(22), contain multiple sialic acid residues, and may contribute
to the negative charge of the clathrin-coated microdomains.
A few studies have demonstrated that caveolae are
involved in AMT, as seen in the transcytosis of cationized
F(ab′)2 antibody fragments across an in vitro BBB model
(23). That being said, it must be pointed out that endocytosis
of cationized F(ab′)2 and Fab fragments can occur in cells
devoid of caveolae (24–26). Furthermore, the intracellular
delivery of Syn-B peptides, a family of cell-penetrating
peptides that exhibit charge-mediated BBB selectivity,
appears to occur via a caveolae-independent pathway (27).
In the same vein, two endocytic pathways have been
described for natural polyamines in various cultured cells:
one would be through receptor-mediated endocytosis via
coated pits (28), and the other via caveolae after binding to
glypican-1 at the exofacial side of the plasma membrane (29).
Transport Properties of AMT
Both in vitro and in vivo studies provide evidence that
brain uptake via AMT and RMT are time- and concentration-
dependent processes which require energy (1). The kinetic of
brain uptake via AMT or RMT across the BBB is as slow as
that which is characteristic of endocytosis: the transport takes
minutes to occur and is much longer than the carrier-mediated
transport of nutrients (e.g. glucose) (30). Although AMT may
not involve binding speciﬁcally to plasma membrane receptors,
both AMT and RMT are saturable transport processes. The
main difference between AMT and RMT lies in that the
former becomes saturated at higher concentrations than
the latter. Indeed, the maximum binding capacities (Bmax)f o r
AMT are of the order of several nanomoles per milligram of
membrane protein (1), values that are several thousand times
greater than those for RMT (Bmax<1 pmol/mg of membrane
protein). However, AMT is also characterized by micromolar
half-saturation constants, as opposed to RMT which has KD
values in the low nanomolar range. Since the occupancy of
binding sites depends on both afﬁnity and capacity, the afﬁnity-
capacity product for AMT is relatively similar to that for RMT.
Fig. 3. Schematic overview of major cell-surface glycan-containing components. The syndecans and
glypicans form the two most common groups of heparan sulfate proteoglycans on the endothelial surface.
The backbone structure of HS consists of N-acetylglucosamine-glucuronic acid disaccharides (n=10–50),
which are modiﬁed by the addition of sulfate groups at various positions. The syndecan family (four
members) consists of transmembrane HSPGs which all have highly variable extracellular domains, but have
homologous transmembrane and cytoplasmic domains. The syndecans exhibit cell-type speciﬁc distribution
with vascular endothelial cells (ECs) expressing syndecan-1, -2, and -4 and predominant targeting to
abluminal surfaces. They are the only HSPGs that penetrate the cytoplasm, thus allowing for interaction
with the cytoskeleton (syndecan-1) or focal adhesion molecules (syndecan-4). Syndecan-1 has both HS and
chondroitin sulfate (CS) glycosaminoglycans (GAGs). The glypicans (six members) possess structural
similarity, and typically differ in the number of GAG attachment sites in the extracellular region. They are
linked to the cell surface through a COOH-terminal GPI anchor (yellow bar in the ﬁgure). In contrast to the
syndecans, glypicans contain HS only. The glypicans are selectively expressed on different cell types with
only glypican-1 present on vascular ECs. These HSPGs are mainly targeted to luminal surfaces. Perlecan
(not represented) is the least common HSPG and consists of only one variant with a total of ﬁve GAG
linkages. Sialylated glycoproteins contain only oligosaccharide chains with alpha- and beta-galactosyl
residues, and alpha-mannosyl/glucosyl residues linked to N-acetylglucosamine. The oligosaccharide chains
are terminated by sialic acid residues in the alpha 2–3 and/or 2–6 linkages. For a review on HSPG, see (13)
460 Hervé, Ghinea and ScherrmannAMT-BASED DRUG DELIVERY STRATEGIES
The physiologically-based strategies developed to in-
crease BBB permeability to hydrophilic and/or large mole-
cules take advantage of the various transport mechanisms
identiﬁed at the BBB. RMT, and more importantly in the
present context, AMT, are good candidates for the transport
of macromolecules. In this section, we will speciﬁcally discuss
the cationization and cell-penetrating peptides, and also the
limitations and pitfalls involved in the investigation and
development of these strategies that use AMT.
Protein Cationization
As seen earlier, AMT is a transport process that applies
to cationic proteins (11). Due to the abundance of polyanions
that surround the BBB, cationization of proteins is a
reasonable choice to endow them with the ability to cross
the BBB via AMT.
Cationization Methods
The simplest way to chemically cationize a protein is the
amidation of its carboxylic acid groups (i.e. carboxy-terminal
group, as well as glutamic (Glu) and aspartic acid (Asp) side
chain groups) with positively charged amines. This reaction is
usually accomplished by the carbodiimide-mediated amidation
of these groups (Fig. 5). The advantage of this type of
modiﬁcation is the direct delivery of the protein itself without
depending on a cationic import carrier. Various diamines and
polyamines, either synthetic or natural, have been attached to
proteins to form amide linkages. Examples of these are given in
Table II. The most widely used polyamine molecule in the case
of BBB transfer is probably the synthetic hexamethylenedi-
amine or HMD (1,9). Yet, there are naturally occurring poly-
amines that have also been used, such as putrescine (PUT),
spermidine (SPD) and spermine (SPM) (10). The interesting
aspect to these three polyamines is their increasing net positive
charge valency. Furthermore, they are ubiquitously present in
all mammalian cells and involved in pathways for posttransla-
tional modiﬁcations of proteins (31). It has been suggested that
the modiﬁcation of these polyamine-conjugated proteins may
facilitate their transport across cell membranes (10).
The extent to which a given protein can be cationized
primarily depends on the amino-acid composition and
conformation of the protein itself, i.e. the greater the number
of accessible carboxyl groups, the higher the degree of
cationization. It also depends on the molar excess of
polyamine and carbodiimide relative to the protein carboxyl
groups (9,26). The polyamine excess prevents protein poly-
merization via intermolecular cross-linking and ensures that
only one terminal amino group of the polyamine couples to
one carboxyl group on the protein. Cationization is a pH-
dependent reaction, and increases as the pH decreases (9,26).
Protein cationization can signiﬁcantly raise the cationic net
charge, which can be identiﬁed by isoelectric focusing.
Procedures involving the use of radiolabeled polyamines can
be used to quantitatively determine the extent of cationiza-
tion of a protein if necessary (25,26).
Sidetracks: Biological Activity and Radiolabeling
Cationization can compromise the protein activity either
by direct derivatization of crucial Asp or Glu residues in the
following locations: sites of antibodies which bind antigens,
sites of enzymes which bind substrates, and in the case of
albumin, sites which bind therapeutic ligands. Cationization of
peptide hormones or growth factors can also alter their binding
to their speciﬁc receptors. Alteration can also take place
through conformational changes. For some proteins, the
biological potency may be completely destroyed after cationi-
zation (9), whereas it may only be altered to a certain extent
for others (26,32,33). A strategy for retaining the activity of
selected proteins may be protein site protection during the
reaction with, for example, the antigen or substrate. The
linkage of the cationizing groups to parts of the protein which
are far from the binding or active domain (e.g. glycan chains of
immunoglobulins) may also be a suitable strategy (1).
The degree of cationization of the protein may be critical
for its pharmacokinetic fate. Mildly cationized albumins with
isoelectric point (pI) values ranging between 7.2 and 9 have
been shown to display more favorable pharmacokinetic
properties than heavily cationized albumins with pI values
of more than 9, both in terms of plasma half-life and
selectivity to brain tissue, as compared to other organs (1).
This should be taken into account when considering the use
of cationized albumin as a possible brain drug transport
vector in vivo. Undesirable effects on the pharmacokinetic
properties of cationized proteins may not necessarily be
linked to cationization in itself, but to the radiolabeling
Fig. 4. Schematic representation of the vesicular transendothelial
pathways in brain capillaries involving the caveolar (1) and the
clathrin-coated pit/vesicle (2) systems. The bold arrows indicate
principal routes of transport from blood to brain tissue; the thin
arrows indicate limited transport from brain towards blood plasma.
Abbreviations: cA, caveolae open to the abluminal front; cC,
cytoplasmic caveolae; cL, caveolae open to the luminal surface of
the cerebral endothelial cells; cpA, clathrin-coated pit open to the
abluminal front; cpL, clathrin-coated pit open to the luminal front;
cvA, clathrin-coated vesicle associated with the abluminal endothelial
surface; cvL, clathrin-coated vesicle associated with the luminal
endothelial surface; V, smooth vesicle; VA, smooth vesicle open to
the abluminal front; VL, smooth vesicle open to the luminal front; j,
tight junction; te, transcytotic endosome
461 CNS Delivery Via Adsorptive TranscytosisTable II. Peptides and Proteins Covalently Modiﬁed with Diamines/Polyamines, and their Potential Use as Neuropharmaceuticals
Diamine/polyamine Protein/peptide Potential applications Refs.
Hexamethylenediamine
(HMD)
Albumin Cationized albumin as drug transport carrier (1)
Cationized albumin-avidin conjugate: delivery
of biotinylated therapeutics
(6)
Albumin/beta-endorphin chimeric peptide (111)
Cationized albumin coupled to liposomes,
as drug carriers
(112)
Anti-betaA4 protein antibodies In vivo diagnosis of Alzheimer’s disease (9)
Anti-epidermal growth factor (EGF)
receptor and anti-tenascin-antibodies
Radio-immunoimaging and radio-immunotherapy
of malignant brain tumors
(9)
Anti-ras oncogene antibodies Intracellular immunization; therapeutics of cancer (9)
Anti-rev protein antibodies Intracellular immunization; therapeutics of HIV-1
infection
(9)
Anti-tetanus toxin antibodies Anti-tetanus therapy (23)
Putrescine (PUT) Anti-amyloid beta peptide antibodies Immunotherapy of Alzheimer’s disease; imaging
of amyloid plaques
(37,113)
Amyloid beta protein 1–40 Diagnosis of Alzheimer’s disease (108)
Beta-sheet breaker peptide Inhibition of amyloidogenesis In vivo; therapy
for Alzheimer’s disease
(109)
Nerve growth factor Treatment of neurological diseases (110)
Superoxide dismutase Treatment of ischemic neuronal degeneration (33)
Catalase Treatment of free radical associated neurodegenerative
disorders
(32)
Treatment of familial amyotrophic lateral sclerosis (32,38,39)
Anti-tetanus toxin antibodies Anti-tetanus therapy (25,26)
Spermidine (SPD)
and Spermine (SPM)
Albumin Polyamine-modiﬁed albumin as drug transport carrier (10)
Nerve growth factor Treatment of neurological diseases (10)
Superoxide dismutase Treatment of ischemic neuronal degeneration (10)
Anti-tetanus toxin antibodies Anti-tetanus therapy (26)
Fig. 5. Schematic of the procedure for the chemical modiﬁcation of a protein by amidation of its carboxylic
acid groups (carboxy-terminal group, Glu and Asp side chain groups) with a diamine or polyamine. The
carboxyl groups on the protein are activated using a carboxyl activator like N-ethyl-N′-3-(dimethylami-
nopropyl)carbodiimide (EDC). The chemical structures of the diamines or polyamines that can be used to
covalently modify proteins for their delivery across the blood-brain barrier are shown. Examples of these
modiﬁed proteins are given in Table II
462 Hervé, Ghinea and Scherrmannmethod used to quantify the plasma and tissue distribution of
these proteins. The in vivo brain uptake of cationized
immunoglobulin G (IgG) may be severely diminished after
protein iodination, due to a serum inhibition phenomenon,
whereas no such inhibitory effect is observed when the same
cationized IgG is tritiated (1,9). Moreover, the same radio-
labeling method applied to two different cationized anti-
bodies can affect their pharmacokinetic behavior differently
(9). This particular point is important when the cationized
protein is intended for use as a radiolabeled tracer in imaging
or treating brain tumors or diseases. Finally there is no rule of
thumb, each protein having to be studied in and of itself. It is
necessary to ﬁnd both the appropriate conditions to cationize
a protein without appreciable loss of potential activity, and a
corresponding radiolabeling method which gives the desired
pharmacokinetic proﬁle in experimental animals (i.e. rapid
plasma clearance and brain uptake).
Limitations and Pitfalls
Random Distribution. A serious limitation for the in vivo
use of cationized proteins is their potentially high adsorptive
p r o p e r t yt o w a r d sa n i o n i cs i t e so fc e l ls u r f a c e s( e . g .H S P G sa n d
phospholipids in the outer leaﬂet of the cell membrane) which
are found in all living cells. This property tends to favour
random tissue and organ distribution of cationized proteins, and
can be a disadvantage for speciﬁc targeting of a desired organ,
particularly when the protein is administered intravenously.
Figure 6 illustrates the rapid and extensive distribution of
cationized anti-tetanus F(ab′)2 as compared to native F(ab′)2
after intravenous administration to rats. Based upon the
respective volumes of distribution calculated for both
antibodies from plasma kinetic data, there is a ten-fold
increase in the apparent tissue distribution of the cationized
F(ab′)2,w h i c hm a yb ep a r t l ye x p l a i n e db yt h ea d s o r p t i o no ft h e
cationized antibody to blood vessel membranes. In order to
ensure that a sufﬁcient dose reaches the desired organ (i.e. the
brain in the present context), higher doses of the cationized
protein must be given. However, at high doses, endothelial
damage is frequently observed resulting from the widespread
deposit of cationized proteins on blood vessel membranes.
Nevertheless, there is no general rule of thumb; in spite
of the risk of non-speciﬁc delivery, brain-speciﬁc distribution of
cationized proteins may well occur (1), as shown in Table II.
Speciﬁc organ delivery of cationic proteins depends on
multiple factors, including dosage and route of administration.
It may also involve speciﬁc interactions between particular
tissue components and the cationic element attached to the
vectorized protein. In this respect, a high level of brain
distribution, compared to the distribution to other organs, was
clearly observed for cationic cell-penetrating peptide vectors
derived from protegrin 1 (34), as described later in this article.
In conclusion, transendothelial organ uptake of cationized
proteins shows considerable variation in different organs and
for different cationized proteins. Therefore, before restricting
cationized proteins to local administration for in vivo use, or to
certain in vitro applications, the efﬁciency of targeting these
proteins to the brain must be evaluated case by case.
Toxicity. The property of cationized proteins to efﬁ-
ciently penetrate cells raises the question of the potential
toxicity and immunogenicity of these proteins. The possible
toxic effects include a generalized increase in vascular
permeability and immune complex formation with associat-
ed membrane nephropathy. A breakdown of BBB perme-
ability and other vascular beds has been observed following
intravenous injection of large amounts of cationic proteins,
but has not been seen when moderate amounts of these
substances were administered (1). It is known that cationic
antigens and immune complexes containing cationic anti-
bodies can deposit in glomeruli, which may result in immune
complex-mediated glomerulonephritis. There are, however,
examples of long-term administration of cationic proteins to
humans without toxic or adverse effects (1,35).
Immunogenicity. The possible immunogenicity of cation-
ized proteins seems to principally reside in pre-existing
immunogenicity to foreign proteins. Indeed cationization of
proteins results in a relatively mild immune response and no
measurable toxic effects when they are administered to
“homologous” animals. Humanized monoclonal antibodies
have been used in high doses in human subjects without
eliciting signiﬁcant immune responses (1). In contrast, “het-
erologous” cationized proteins used even at low doses have
been shown to be highly immunogenic (36). In view of this,
human proteins or recombinant humanized proteins should
be used for cationization and subsequent applications in
humans. As the conjugation of proteins to polyethylene glycol
has been shown to decrease their immunogenicity, PEGyla-
tion of cationized molecules may be an alternative to
minimize the immunogenic potential of these molecules.
Examples of Diamine/Polyamine Modified Proteins that Cross
the BBB
In spite of the aforementioned drawbacks, cationization
has found its place in BBB transport of proteins and peptides.
Table II gives examples of these and also the potential
Fig. 6. Pharmacokinetics in rats of native and cationized anti-tetanus
F(ab′)2 antibody fragments. The ﬁgure shows the plasma concentra-
tion-time curves, after intravenous bolus injection in the femoral vein
of anesthetized rats, of
125I-labeled native F(ab′)2 (upper curve) and
125I-labeled cationized F(ab′)2 (lower curve). The dose of antibody
injected to the rats was 700 mg/kg or 120 μCi/kg for both the
cationized and native F(ab′)2. Data are mean±SD (n=5 rats for each
antibody; JM Scherrmann, unpublished results)
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table, their covalent modiﬁcation with a diamine or polyamine
has been shown to greatly enhance their transport across the
BBB in vivo (1,10)o rin vitro (1,9,23). Most of the examples
given highlight future biomedical prospects rather than actual
applications. Nevertheless, antibodies cationized with synthetic
(i.e. HMD) or natural (i.e. PUT) diamines have been used to
protect the brain against viral antigens and oncogenes in
tumors, and also to image speciﬁc antigens in tumors or beta-
amyloid deposits in subjects with Alzheimer’s disease (1,9,37).
The dramatic increases of BBB permeability to superoxide
dismutase (33) and catalase (32,38,39) covalently modiﬁed with
PUT may enhance the therapeutic usefulness of these anti-
oxidants in treating neurodegenerative diseases (32,33). The
cellular uptake of anti-tetanus F(ab′)2 fragments by both non-
endothelial (HL60) cells (26) and rat brain endothelial (RBE4)
cells in culture (F. Hervé, unpublished results), is markedly
increased after antibody conjugation to the natural polyamines
SPD and SPM. The ability of cationized anti-tetanus F(ab′)2 to
cross the BBB has also been demonstrated (23). The
cationized anti-tetanus F(ab′)2 retained their antigen-binding
activity after endocytosis (25,26) or transcytosis (23). This
supports the possibility of using these antibodies in the
treatment of tetanus, a severe disease of the CNS.
Alternative intracellular delivery strategies of proteins
assisted by cationized carrier proteins have also been
described and can be of interest for future study. They use
protein–protein or ligand–protein interactions that are both
speciﬁc and of high afﬁnity, and since the carrier proteins are
cationized, the direct cationization of the protein to be
delivered is not necessary (40). Cationized carrier proteins
used as models are avidin and protein G. Merely mixing an
antibody with cationized protein G or a biotinylated protein
with cationized avidin is necessary. Nonetheless, these
systems have never been used for brain delivery.
Alternative Transport Mechanisms of Polyamine-Modified
Proteins
Most studies with cationized proteins have pointed to an
adsorptive-mediated transport mechanism across the BBB.
Nevertheless it must be stressed that some authors have
suggested that the increased BBB permeability to proteins
covalently modiﬁed with natural polyamines (PUT, SPD and
SPM) may imply mechanisms of transport other than simple
electrostatic interaction involving charge density (10). Inﬂux
and efﬂux carrier-mediated transport processes exist at the
BBB, some of them possibly being involved in the transport
of polyamines from blood to brain. Examples of these
membrane-bound transporters can be seen in the choline
transporter (41), and members of the OCT/OCTN family,
which transport organic cations, including carnitine and
neuromediators (42). Binding of substrates to membrane-
bound transporters is thought to induce the formation of
transient narrow pores, which then allow the passage of
substrate molecules. Therefore, even if polyamines could
enter the cerebral ECs via the above-mentioned transporters,
it is unlikely that these small molecules could be used as
vectors for the transport of larger molecules, such as peptides
or proteins. On the other hand, endocytosis has been shown
to be an integral part of the transport of polyamines into
various cultured cells (28,29). The possibility that polyamines
may be transported in this way at the BBB remains to be
explored, as also does the possibility that they may undergo
endocytosis when carrying macromolecules.
Other AMT-based strategies for protein delivery to the
brain have been proposed, which include cationic liposomes
(43,44) and cell-penetrating peptides. The following section
will focus on the latter.
Cell-Penetrating Peptides
Discovering that small peptides derived from protein-
transduction domains have the ability to translocate the
cellular membranes and gain access to the cell interior, and
more importantly, allow the cellular delivery of conjugated or
fused biomolecules has opened up new gateways in the ﬁeld
of drug discovery (45). This section will touch on cell-
penetrating peptides generally speaking and their mecha-
nisms of internalization. From there, a selection of these
peptides will be described leading to their potential use for
transport of small drugs and protein-based large molecule
drugs. And ﬁnally, we will see the limitations and pitfalls of
the CPP approach.
Table III. A Selection of Commonly Used Cell-Penetrating Peptides
Cell-penetrating peptides Sequence Origin Refs.
Amphipathic sequences
Penetratin(43–58) or pAntp43–58 RQIKIWFQNRRMKWKK Drosophila melanogaster transcription
factor
(45)
Amphipathic model peptide KLALKLALKALKAALKLA Synthetic (114)
Transportan GWTLNSAGYLLKINLKALAALAKKIL Chimeric galanin-mastoparan (115)
SBP MGLGLHLLVLAAALQGAWSQPKKKRKV Chimeric Caiman crocodylus Ig(v)
light chain-SV40 large T antigen
(116)
FBP GALFLGWLGAAGSTMGAWSQPKKKRKV Chimeric HIV-1 gp41-SV40 large T
antigen
(117)
Cationic sequences
HIV Tat peptide (48–60) GRKKRRQRRRPPQ Viral transcriptional regulator (48)
Syn-B1 RGGRLSYSRRRFSTSTGR Protegrin 1 (34)
Syn-B3 RRLSYSRRRF Protegrin 1 (34)
Homoarginine peptides
((Arg)7 and (Arg)9)
RRRRRRR(RR) Synthetic (57,118)
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So-called CPPs originate from various families (Table III).
They are heterogeneous in size (10–27 amino acid residues)
and sequence, but they all possess several positive charges.
Some of them share common features such as an amphipathic
sequence and the ability to interact with a lipid membrane
(46). The CPPs derived from natural proteins include the
transcription-activating factor Tat, penetratin, and the Syn-B
vectors (Table III). A number of other CPPs are the result of
the engineering of various short peptides like the homoargi-
nine vectors, the model amphipathic peptide and transportan.
Transportan and other chimeric peptides, such as the sequence
signal-based peptide (SBP) and the fusion sequence-based
peptide (FBP), contain sequences of various functions to reach
synergistic translocation efﬁciency (Table III).
Mechanisms of Internalization
Evidence about the exact mechanisms of internalization
of CPPs is scarce, and often elusive and different from one
report to another. This controversy, however, may reﬂect the
possibility that different peptides utilize different uptake
mechanisms depending on their cargo and biophysical
properties, or that CPP membrane translocation is mediated
by several different pathways that may occur simultaneously
(47).
Based on early studies, it has commonly been accepted
that the internalization of CPPs was energy-independent and
did not involve endocytosis, since internalization was not
inhibited by low temperatures, depletion of the cellular ATP
pool, or by inhibitors of endocytosis (45,48). It was also seen
to be neither saturable nor dependent on cell type (49). Both
passive transfer through the lipid bilayer of the plasma
membrane as well as the formation of inverted micelles (45)
have been postulated as possible translocation mechanisms,
whereby the CPPs ﬁrst bind to the lipid bilayer through
electrostatic interaction (50). However, possible electrostatic
interaction with other cell surface components cannot be
ruled out (27,51). If the postulated mechanisms seem to
explain some aspects of CPP translocation and still appear to
hold for peptides exhibiting lipid-binding capacity, it would
seem unlikely that these mechanisms apply to highly hydro-
philic CPPs (52). Moreover, there is no indication of
increased membrane permeability in the presence of hydro-
philic peptides. In fact, later studies have shown that CPP
translocation is mostly a temperature-dependent process (53)
and have established the possible role of endocytosis in the
internalization of CPPs (52,54,55). Given this newly found
pathway, the question as to whether CPPs use receptor- or
adsorptive-mediated endocytosis is raised. Structure-activity
studies have shown that retro-, enantio- and/or retro-enantio
analogues of CPPs retained the internalization properties of
their parent peptides (34,45,53,56), indicating that internali-
zation does not depend on their speciﬁc primary sequences.
This implies non-dependent stereospeciﬁc receptor recogni-
tion. CPPs have an obvious common feature in their cationic
nature. Several studies have highlighted the crucial role of
basic residues in the translocating ability of CPPs (48,51,56).
Of relevance to this is experimental evidence that HSPGs
and/or other negatively charged cell surface components
would take part in this function (13,46,54,57). Where does
this lead if not to adsorptive-mediated endocytosis?
Selected CPPs
Tat-Derived Peptides. The Tat protein is an 86 amino acid
t r a n s c r i p t i o nf a c t o ri n v o l v e di nt h er e p l i c a t i o nc y c l eo fH I V - 1
v i r u s .I th a sb e e nd e m o n s t r a t e dt ob er a p i d l yt a k e nu pb yc e l l s
and to concentrate in the nucleus. The functional domain
responsible for cell and nucleus import is the basic region
extending from residues 49 to 58 (58). Since its initial
description, many truncated versions of Tat which derived
from this basic region have been described and shown to
penetrate different cell types (48). Structure-activity relationship
studies of the fragment Tat(38–60) and further truncated forms
of this sequence, revealed that the whole basic region of Tat
w a sap r e r e q u i s i t ef o rc e l l u l a rp e p t i d eu p t a k e( 53,56). One of
the shortest peptides, Tat(48–60), which contains a nuclear
localization signal, was deﬁned as the minimal translocating
peptide. Analogues of the peptide corresponding to its retro-,
enantio- or retro-enantio form penetrated cells as efﬁciently as
the parent peptide (53,56). However, deletion of one or two
arginine residues in the peptide sequence resulted in a
signiﬁcant or dramatic reduction of the cell-penetrating ability,
while the deletion of three non-basic residues within this
sequence did not affect the translocation property.
It has been suggested that the full-length Tat protein
follows an adsorptive-mediated endocytic mechanism when
internalized (59). The same internalization mechanism was
also proposed for the green ﬂuorescent protein (GFP)-Tat
protein conjugate (60). Tat conjugated to ﬂuorescent probes
(59) or cargo proteins (61) was seen to be conﬁned within
cytoplasmic vesicles corresponding either to endosomes or
lysosomes. Internalization of Tat protein was inhibited by
heparin, but not by chondroitin sulfates, suggesting the
possible involvement of HSPGs in the uptake mechanism
(62). An inhibition of uptake was also demonstrated with
other polyanions, such as suramin and pentosan sulfate (63).
Furthermore, it has been shown that internalization of GFP
fused to Tat protein is caveolae-mediated (55,64). It was also
suggested that the uptake mechanism might involve an
interaction of the Tat protein with the sugar moiety of cell
surface glypicans. In addition to the full-length Tat protein,
the Tat-derived peptide (48–60) also seems to follow an
energy- and temperature-dependent endocytic mechanism for
its cellular internalization (52). The Tat(48–60) uptake, as well
as that of Tat(48–60)-peptide nucleic acid (PNA) conjugate,
were shown to be time-, temperature- and concentration-
dependent (52,65). After internalization, the peptide and
conjugates have been shown to display a characteristic endo-
somal distribution resulting in colocalization with common
endocytic markers. Moreover, the role played by cell surface
HSPGs in the uptake of Tat(48–60) and Tat fusion proteins
reinforced the possibility of an adsorptive endocytic process
(54,66). GFP fused to Tat(48–58) showed the use of the same
internalization mechanism as GFP fused to the full-length Tat
protein, as seen above (55).
Syn-B Vectors. This peptide family is derived from the
natural antimicrobial peptide protegrin 1 (PG-1) originally
isolated from porcine leukocytes. PG-1 is an 18 amino acid-
465 CNS Delivery Via Adsorptive Transcytosislong peptide with an antiparallel beta-sheet structure stabilized
by two disulﬁde bridges (46). It interacts with, and forms pores
in the lipid matrix of bacterial membranes (67). Various linear
analogues of PG-1 that lack cysteine residues have been
designed, which are devoid of the membrane-disrupting
activity of PG-1. These linear peptides known as the Syn-B
vectors, are able to interact with the cell surface and efﬁciently
cross the plasma membrane (27,68). Further optimizations
have led to the development of shorter peptides (less than ten
amino acids) that have improved translocation properties. As
for the Tat-derived peptides, internalization of the Syn-B does
not depend on a stereospeciﬁcr e c e p t o r( 34,46). Syn-B peptides
have been associated with adsorptive-mediated endocytosis
(34,46). Indeed, their transport into cells was demonstrated to
be both energy-dependent and saturable, and inhibited in a
competitive manner by polycationic molecules, such as poly-L-
lysine and protamine. Moreover, the KD values measured for
the Syn-B transport reside in the micromolar range, and
compare well with the values observed for molecules described
as being taken up by adsorptive-mediated endocytosis. Similar
characteristics of transport were demonstrated for the cell
uptake of Syn-B vectors conjugated to a ﬂuorophore (27)o r
various drugs (34,69,70).
Other Cell-Penetrating Peptides. The highly hydrophilic
and cationic nature of poly-arginine (Arg) peptides makes
endocytosis a likely pathway for their internalization. Indeed,
the cellular uptake of (Arg)9 and its PNA conjugate was seen
to follow an energy-dependent endocytic pathway, with
characteristics similar to those demonstrated for Tat(48–60)
anditsPNAconjugate(52). The use of a similar internalization
pathway was also demonstrated for polyarginine (Arg)8 and
poly-lysine (Lys)8 fused to the GFP (71).
Many other peptides have been reported to have cell-
penetrating properties, some examples of which are given in
Table III. Several reviews have taken the time to cover these
peptides and their respective internalization mechanisms in
greater detail (46,72,73). Adsorptive-mediated endocytosis
was suggested for penetratin (residue sequence 43–58)
(27,51), biotinylated penetratin(43–58) bound to avidin or
streptavidin (54), and for penetratin (residue sequence 42–58)
conjugated to PNA (65), as well as for transportan conjugated
to gold particles (74). However, other hypotheses have also
been proposed to explain the transport mechanism. In fact,
studies dealing with the kinetics of uptake show that the
delivery process of these peptides may use two mechanisms
simultaneously: a slow endocytic process and a rapid cellular
penetration by passive diffusion across the lipid bilayer
(74,75). Formation of inverted micelles was also a proposed
mechanism for the uptake of penetratin (45).
In vitro Delivery to Cells and in vivo Delivery to Brain Tissue
Examples of cargo delivery using CPPs are given in
Table IV. Some general comments need to be made before
going further. Although CPP vector-mediated strategies have
proven their efﬁciency in carrying a variety of molecules into
cells, evidence demonstrating the capacity of CPPs and CPP-
cargo constructs to permeate complex physiological barriers,
Table IV. Examples of Cargos Delivered by Selected Cell-Penetrating Peptides
CPPs Cargos In vivo brain delivery
In vitro cell
delivery Refs.
L-Penetratin Antisense oligonucleotides ✓ (119,120)
GFP ✓ (121)
LFG ✓ (122)
p21(WAF1) ✓ (123)
PNA ✓ (124)
D-Penetratin Doxorubicin ✓ (34,81)
Tat protein and Tat-derived peptides Antisense oligonucleotides ✓ (120)
Bcl-xL fusion protein ✓ (78,79)
Beta-galactosidase ✓ (77)
Beta-galactosidase ✗✓ (61)
Caspase-3 ✓ (125)
Domain III of Pseudomonas exotoxin A ✓ (61)
Fab antibody fragment ✓ (126)
GFP ✓ (127)
Horseradish peroxidase ✓ (61)
RNase A ✓ (61)
p16INK4a ✓ (128)
Syn-B vectors Benzyl-penicillin ✓ (70)
Dalargin ✓ (69)
Doxorubicin ✓ (34)
Morphine-6-beta-d-glucuronide ✓ (76)
FBP Oligonucleotides ✓ (129)
Homoarginines PNA ✓ (52)
✓ Brain or cell delivery, ✗ no brain delivery, GFP green ﬂuorescent protein, LFG peptide motif serving as a docking site for cyclin/cyclin-
dependent-kinase (cyclin-Cdk) complexes, p21(WAF1) cyclin inhibitor, PNA peptide nucleic acid; Bcl-xL death-suppressing molecule of the
Bcl-2 family, p16INK4a inhibitor of cyclinD:Cdk4/6.
466 Hervé, Ghinea and Scherrmannsuch as the BBB, is still rare. Secondly, the therapeutic value
of the CPP approach needs further documentation. Indeed,
many cargo models used to demonstrate the ability of CPPs
to efﬁciently translocate small or large molecules into cells—
for example ﬂuorescent probes or the GFP or beta-galacto-
sidase tags—have no therapeutic value whatsoever. However,
there are several examples where CPPs have been used
successfully to deliver therapeutic molecules through the
BBB and into the brain, but as it stands today, most examples
are limited to low molecular weight drugs and small peptide
drugs (34,69,70,76).
The ﬁrst benchmark study of the ability of CPPs to
deliver proteins across the BBB is probably that of Schwarze
and Coll. (77) (Table IV). In this study, the authors examined
the biodistribution of the Tat-derived peptide (47–57) fused
to beta-galactosidase after intraperitoneal injection in mice. A
strong beta-galactosidase activity was found in practically all
tissues including the brain, demonstrating that the fusion
protein had not only passed into many other tissues, but it
had also crossed the BBB. Subsequently, various authors
have used the Tat-based delivery approach for the transport
of the Bcl-xL protein, a well-characterized death-suppressing
molecule. Intraperitoneal injection of Bcl-xL fused to Tat into
a murine stroke model has been shown to decrease cerebral
infraction and attenuate ischemia-induced caspase-3 activa-
tion in ischemic neurons (78). Another study conﬁrmed the
neuroprotective effect of Bcl-xL fused to Tat following
intravenous injection in animal models of ischemic brain
injury (79). However, there is other evidence showing that
well-differentiated epithelial cells were essentially non-per-
meable to Tat(47–57) under physiological conditions (80).
Furthermore, Tat peptides (1–72) or (37–72) conjugated to
beta-galactosidase showed no penetration into the brain
following intravenous injection, while a high tissue-associated
activity was found in many other organs (61). Therefore, it is
necessary to reconsider the general belief that CPP-mediated
delivery may be technologically superior to commonly used
delivery agents because of the practically unlimited systemic
access of CPPs and potential for systemic drug delivery across
cellular barriers.
Nevertheless, Syn-B vectors apparently enhance the
delivery of different types of molecules across the BBB in
vivo (Table IV). For example, the anticancer agent, doxoru-
bicin, does not cross the BBB due to the presence of the P-
glycoprotein (P-gp). Syn-B’se f ﬁciency in enhancing the brain
uptake of doxorubicin has been demonstrated using in situ
cerebral perfusion in rats and mice (34). Not only was the
BBB integrity left uncompromised, but the Syn-B vectorized
doxorubicin bypasses the P-gp (81). In comparison, there was
a much smaller increase of BBB permeability to doxorubicin
conjugated to D-penetratin; this permeability was possibly
caused by the opening of the tight junctions. The ability of
Syn-B vectors to enhance the brain uptake of doxorubicin
was further assessed after intravenous injection of vectorized
doxorubicin in mice (34). Signiﬁcantly higher levels of the
vectorized drug were measured in the brain, as compared to
unmodiﬁed doxorubicin. Since these ﬁrst promising studies,
conjugating other pharmaceuticals to Syn-B vectors, such as
benzyl penicillin (70), dalargin (69) and morphine-6-glucuro-
nide (76), has shown to improve the uptake of these small
cargos.
Limitations and Pitfalls
The ability of CPPs to penetrate many cell types in vitro,
as well as in vivo greatly restricts their application as
pharmaceutical tools. This is why targeted CPP delivery
strategies need to be developed. Such strategies may exploit
speciﬁc cell features, such as extracellular receptors or
enzymes (82), or use small or large cell-binding ligands (e.g.
vitamins, growth factors or antibodies) which, when incorpo-
rated into CPPs, may render these cationic peptides capable
of distinguishing between non-target and target cells (83).
Other problems are related to the stability of CPPs, and their
toxicity and immunogenicity.
Stability. The stability of peptide vectors is an important factor
regarding their use for in vivo delivery. The vector must not be
metabolically cleaved until it delivers its cargo to the appro-
priate target. Only a few studies have investigated the cellular
metabolism of CPPs. One of them examined and compared the
stability of transportan, a transportan analogue, and penetratin
(43–58) (84). The metabolic stability of the two former
peptides was shown to be superior to that of penetratin.
Another study showed the greater stability of Tat(47–57) also
compared to penetratin (72). Stabilization of the peptide
vectors may be achieved by using the D-form of the peptide,
instead of the naturally occurring L-amino acids (85). The D-
form is less sensitive to degradation by proteases and remains
intact for a longer time than the L-form when injected in vivo.
Vector stability may also be enhanced by using peptide mimics
such as beta-peptides (86)o rp e p t o i d e s( 56). On the one hand,
the vector must be protected from degradation until it reaches
the target; on the other hand, its subsequent degradation or
removal is a prerequisite for the release of the transported
cargo, leaving it free and able to exert its activity. However,
premature cleavage of the CPP-cargo constructs may result in
acute or chronic toxicity when used for therapeutic purposes.
Toxicity and Immunogenicity. Both toxicity and immu-
nogenicity are other problems with CPPs. Various CPPs have
been shown to exert a toxic action on cultured cells. The full-
length Tat protein and the Tat-derived peptides produced
toxic effects on rat neuronal cultures, the importance of which
was seen to depend on the length of the peptide (72). Thus,
the full-length Tat protein produced lower levels of neuro-
toxicity than the shorter peptides Tat(31–71) and Tat(31–61)
in that order. Both the cysteine-rich domain extending from
residues 32 to 47 and the basic domain (positions 48–57) seem
to be essential for neurotoxicity. Both regions were also
demonstrated to induce endothelial cell apoptosis (87) and
exert toxicity on HeLa cells (48). However, peptides contain-
ing only the basic region Tat(48–57) did not induce signiﬁcant
toxicity on cells, even when used at concentrations up to
100 μM( 48,87). In comparison, penetratin(43–58) used at
concentrations in the range of 40–100 μM produced cytotoxic
effects (27,72). Homoarginine peptides have been shown to
alter the integrity of epithelial cell barriers in vitro (88), and
to induce inﬂammation in rat lungs after intraperitoneal
injection or intratracheal administration (89). The high
adsorptive capacity of these cationic peptides to negatively
charged surfaces in the pulmonary epithelium have been
suggested to cause death after intratracheal administration.
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Nevertheless it has to be stressed that most CPPs are derived
from non-human proteins and, in the case of administration
to humans, these peptides have the potential to induce an
immune response. This risk may be considerably increased
when these small carriers are conjugated to macromolecules.
CONCLUSION
Many leading protein drug treatments for brain diseases
have been identiﬁed, and these may yield more favorable
therapeutic indices than small molecule therapeutics. How-
ever, proteins do not cross the BBB and have little chance
of being successful as brain drugs. The protein drug
candidates need to be modiﬁed to overcome this transport
obstacle. This may be done by the direct conversion of the
protein carboxyl groups into extended primary amino
groups (i.e. the cationization approach), or by the attach-
ment of a cationic import peptide to the protein by chemical
conjugation or genetic fusion (i.e. the CPP approach), in
order to trigger transport across the BBB via an adsorptive-
mediated process (AMT). Cationization or the use of CPPs
endows proteins with the ability to rapidly adsorb to
negatively charged cell membranes and thus to penetrate a
variety of different cells. These properties can interfere with
speciﬁc brain targeting. On the other hand, the particularly
high density of the capillary network of the brain may result
in a high concentration of negative charges at the BBB. This
concentration would create an environment selective for
positively charged substances, and make AMT-based deliv-
ery strategies feasible, leading to the development of
protein-based neurotherapeutics. Although the ability of
cationization and CPPs to enhance the transport of proteins
across cell membranes and the BBB is now well docu-
mented, the detailed mechanism by which molecules can
bind to and cross the BBB via AMT remains unclear. What
is known is that these molecules are internalized at the
luminal side of the cerebral ECs, into membrane-bound
vesicles after binding to various, not yet clearly identiﬁed,
cell surface components bearing anionic sites. These mole-
cules can then transcytose directly to the opposite side of the
cell, or trafﬁc inside the ECs in different ways, either
accumulating in lysosomal compartments for degradation or
eventually crossing the cell.
In view of these drawbacks, it is necessary to improve
the brain targeting and clinical utility of protein drug
delivery via AMT. One step would be to examine and
identify the anionic components involved in the binding of
cationized and CPP-vectorized proteins at the luminal
membrane of the cerebral ECs. In addition, a better
knowledge of the endocytic mechanisms involved in AMT
would be helpful in avoiding lysosomal degradation in the
ECs and in achieving transport of intact molecules to the
underlying brain tissue. Glycomic and proteomic research
would be useful in this area. Once the anionic sites have been
identiﬁed and their binding properties determined, designing
appropriate amino acid sequences of cationic vectors for the
AMT process might be feasible. Additional factors like
molecular weight as well as the cationic charge density also
have to be considered when tailoring peptide vectors to
increase AMT efﬁciency. Improving the brain selectivity of
cationization- and CPP-based protein drug delivery strategies
should also help decrease the dose necessary to obtain
therapeutic efﬁcacy, and this would, in turn, reduce the risks
of toxicity and immunogenicity. Furthermore, it is clear that
research focusing on the pharmacokinetic properties of
cationized proteins and cationic import vectors cannot be
neglected. Experimental evidence shows that brain-speciﬁc
delivery of these molecules is often hampered by interactions
with circulating proteins (e.g. serum albumin and alpha-1-acid
glycoprotein) as well as with blood cell membranes, when
these molecules are administered intravenously. This can lead
to a decrease of the amount of the protein drug available for
transfer into the brain. To improve drug delivery via AMT for
the treatment of neurological diseases, we must reformulate
the protein drug candidate or use galenic strategies to avoid
undesirable interactions, and to protect the cationic proteins/
vectors from enzymatic degradation. In order to limit the
effects of ﬁrst pass blood ﬂow, chemical techniques such as the
PEGylation of the target macromolecule could be more widely
used. Indeed, decorating the cationic proteins with PEG
molecules masks the positive charges which, in turn, helps to
limit interactions with peripheral tissues, prolongs circulatory
time and reduces immunogenicity. In addition, new delivery
systems should be developed or existing systems used more
effectively. Coupling to cationic polymers, using liposomes, or
developing new devices from nanovector technology may lead
to high cerebral transfer of the target molecule and low
toxicity. Future research should also focus on the routes of
administration of protein drugs. Ideally, routes no more
invasive than an intravenous or subcutaneous injection should
be used in AMT-based brain drug delivery strategies. Unfor-
tunately, some routes of delivery of cationized proteins,
intravenous and intrapulmonary, result in severe adverse
effects. Strategies as diverse as aerosolization of the target
molecule—which distributes substances over a wider absorp-
tion surface than intravenous injection—new formulations or
transient immune suppression should be re-examined in the
context of increased efﬁciency of brain delivery and decreased
immune response. Finally, combination strategies may also be
used to increase the delivery of therapeutic molecules across
the BBB. For example, it would be possible to associate the
delivery strategy with another strategy for opening tight
junctions reversibly (8) or for disrupting the polarization of
phospholipids across cell membranes (90). Based upon
progress in these multiple directions, we can reasonably
expect that AMT will become an efﬁcient physiologically-
based process for the brain delivery of protein drugs with a
low permeability across the BBB.
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